[Press release – not published yet] Phase 3 prevention trial showed 81% reduced risk of symptomatic SARS-CoV-2 infections with subcutaneous administration of monoclonal antibodies

Phase 3 prevention trial showed 81% reduced risk of symptomatic SARS-CoV-2 infections with subcutaneous administration of REGEN-COV™ (Casirivimab with Imdevimab) – Regeneron

Commentaries: Regeneron says antibody cocktail prevented Covid when given as simple injection, not an IV – STAT AND Regeneron’s Covid mAb as a prophylactic injection: Reduced risk of symptomatic infection by 81% – Endpoint News